Barinthus Biotherapeutics (BRNS) Expected to Announce Earnings on Thursday

Barinthus Biotherapeutics (NASDAQ:BRNS) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Barinthus Biotherapeutics to post earnings of ($0.29) per share and revenue of $0.2170 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 12:30 PM ET.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its earnings results on Thursday, April 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.14.

Barinthus Biotherapeutics Price Performance

BRNS opened at $0.57 on Thursday. The business’s 50-day moving average price is $0.66 and its two-hundred day moving average price is $0.65. Barinthus Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.83. The company has a market capitalization of $23.44 million, a price-to-earnings ratio of -0.44 and a beta of -0.41.

Institutional Investors Weigh In On Barinthus Biotherapeutics

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Baird Financial Group Inc. grew its stake in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,461 shares of the company’s stock after acquiring an additional 100,000 shares during the period. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent quarter. Institutional investors own 25.20% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.